Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2023-09-11 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
112年8月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report from a publicly listed company, showing monthly and cumulative net operating revenue figures with comparisons to the prior year. It includes notes on accounting standards (IFRS) and reporting practices. The document is short (773 characters) and primarily provides financial summary data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release with key highlights. It is a regulatory disclosure of financial data but not a full report. Given the short length and nature, it fits best as a Regulatory Filing (RNS) which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2023-09-11 Chinese
112年08月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, chairpersons, general managers, and their family members. It lists the number of shares held, changes in holdings, and related information. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement about voting or dividends. The document is a report of personal share transactions and holdings by company directors and executives, which matches the definition of Director's Dealing (DIRS). The document length is substantial and contains actual data, not just an announcement or certification, so it is not RNS or RPA.
2023-09-07 Chinese
112年08月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current and initial shareholdings, pledged shares, and related party holdings. It is a disclosure of insider shareholdings and changes, typical of a Director's Dealing or insider share transaction report. There is no indication of financial statements, earnings data, or meeting materials. The document length is 3702 characters, which is relatively short but contains detailed insider shareholding data. This matches the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives. Therefore, the correct classification is DIRS with high confidence.
2023-09-07 Chinese
112年第2季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a financial disclosure related to investment in overseas subsidiaries, showing investment amounts, shareholding percentages, and recognized investment gains or losses for the current period. It is a tabular financial data report with notes explaining accounting treatments. The document length is short (1069 characters) and it does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It is more of a regulatory disclosure of investment details, likely a regulatory filing. There is no indication of it being an announcement of a report publication, nor is it a certification or officer attestation. It does not fit into other specific categories such as earnings release, capital update, or management report. Therefore, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2023-08-14 Chinese
112年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment information related to the company's investments in mainland China, including capital amounts, investment methods, cumulative investment amounts, and recognized investment gains or losses. It includes notes explaining the investment methods and accounting bases for investment gains/losses. The document is relatively short (1509 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report or announcement. There is no indication that this is an annual or interim report, audit report, or earnings release. It is a specific regulatory disclosure related to investment activities, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-08-14 Chinese
112年第2季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data specifically showing a consolidated statement of changes in equity for the first half of the year 2023 (民國112年上半年度) and the same period in the previous year. It includes line items such as common stock, capital surplus, legal surplus reserve, special surplus reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, and total equity attributable to the parent company and non-controlling interests. The presence of actual financial figures and comprehensive equity changes for a half-year period indicates this is a substantive financial report for a period shorter than a full fiscal year. The document length is 3761 characters, which is sufficient to contain detailed financial data rather than just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2023-08-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.